• Atara Biotherapeutics announced board changes, with Carol Gallagher departing after 13 years as a director.
• Brian Cherry appointed to the board; former Managing Partner at Oak Hill Capital with 25+ years in buyout and growth equity investing.
• Cherry has led healthcare and other sector investments totaling more than $25 billion in enterprise value, bringing capital allocation and M&A experience.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atara Biotherapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606121600BIZWIRE_USPR_____20260612_BW613594) on June 12, 2026, and is solely responsible for the information contained therein.